FIG. 10.
Percentage of study eyes that remained in the study with no additional IOP-lowering treatment (topical medication or laser/surgery) after a single administration of Bimatoprost SR in the phase 1/2 APOLLO study. Adapted from Craven et al.,111 under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/).